Cargando…

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer

Background: The association between optimal carbohydrate antigen (CA) 19-9 concentration after neoadjuvant chemotherapy (NACT) and prognosis has not been confirmed in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC). Methods: This retrospective study included...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Woohyung, Park, Yejong, Kwon, Jae Woo, Jun, Eunsung, Song, Ki Byung, Lee, Jae Hoon, Hwang, Dae Wook, Yoo, Changhoon, Kim, Kyu-pyo, Jeong, Jae Ho, Chang, Heung-Moon, Ryoo, Baek-Yeol, Park, Seo Young, Kim, Song Cheol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291310/ https://www.ncbi.nlm.nih.gov/pubmed/32423123 http://dx.doi.org/10.3390/jcm9051477

Ejemplares similares

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2020)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
por: Yoo, Changhoon, et al.
Publicado: (2019)

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
por: Lim, Dong-Hoon, et al.
Publicado: (2023)

Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadrenal Infiltration
por: Kwon, Jaewoo, et al.
Publicado: (2021)

Evaluation of postoperative outcomes of minimally invasive distal pancreatectomy for left-sided pancreatic tumors based on the modified frailty index: a retrospective cohort study
por: Park, Yejong, et al.
Publicado: (2023)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
por: Sung, Min Kyu, et al.
Publicado: (2021)

Lack of Association between Postoperative Pancreatitis and Other Postoperative Complications Following Pancreaticoduodenectomy
por: Yoo, Daegwang, et al.
Publicado: (2021)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
por: Yoo, Changhoon, et al.
Publicado: (2021)

Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma
por: Hong, Sarang, et al.
Publicado: (2021)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Predictive Factors Associated with Complications after Laparoscopic Distal Pancreatectomy
por: Song, Ki Byung, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer
por: Jun, Eunsung, et al.
Publicado: (2021)

Surgical Decisions Based on a Balance between Malignancy Probability and Surgical Risk in Patients with Branch and Mixed-Type Intraductal Papillary Mucinous Neoplasm
por: Lee, Seung Jae, et al.
Publicado: (2020)

Prognostic Predictability of American Joint Committee on Cancer 8th Staging System for Perihilar Cholangiocarcinoma: Limited Improvement Compared with the 7th Staging System
por: Lee, Jong Woo, et al.
Publicado: (2020)

Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma
por: Lee, Jong Woo, et al.
Publicado: (2021)

The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay
por: Jun, Eunsung, et al.
Publicado: (2020)

Usefulness of Inflammation-Based Prognostic Scores in Patients with Surgically Treated Pancreatic Ductal Adenocarcinoma
por: Hong, Sarang, et al.
Publicado: (2021)

Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: Three case reports and a literature review
por: Sung, Min Kyu, et al.
Publicado: (2023)

Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
por: Park, Yejong, et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

A Comparative Study of Laparoscopic versus Open Pancreaticoduodenectomy for Ampulla of Vater Carcinoma
por: Yoo, Daegwang, et al.
Publicado: (2020)

Effect of Flowable Thrombin-Containing Collagen-Based Hemostatic Matrix for Preventing Pancreatic Fistula after Pancreatectomy: A Randomized Clinical Trial
por: Park, Yejong, et al.
Publicado: (2020)

Comparison of Minimally Invasive versus Open Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Propensity Score Matching Analysis
por: Kwon, Jaewoo, et al.
Publicado: (2020)

Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma
por: Yoo, Daegwang, et al.
Publicado: (2020)

Comparison of perioperative outcomes in pancreatic head cancer patients following either a laparoscopic or open pancreaticoduodenectomy with a superior mesenteric artery first approach
por: Park, Min Young, et al.
Publicado: (2021)

Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients
por: Kwon, Jaewoo, et al.
Publicado: (2020)

Stereotactic body radiation therapy for locally advanced pancreatic cancer
por: Jung, Jinhong, et al.
Publicado: (2019)

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
por: Kim, Bum Jun, et al.
Publicado: (2017)

The survival impact of surgical waiting time in patients with resectable pancreatic head cancer
por: Seo, Hye Kyoung, et al.
Publicado: (2018)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
por: Jeong, Hyehyun, et al.
Publicado: (2021)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Radiation therapy for recurrent extrahepatic bile duct cancer
por: Koh, Minji, et al.
Publicado: (2021)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only
por: Shin, Su-Jin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tqucno96hd5uo0fvatc2ltuomq